Ubrogepant
ATC Code
N02CD04
Ubrogepant
Definition
An orally bioavailable calcitonin gene-related peptide (CGRP) receptor antagonist that can be used in the acute treatment of migraines. Upon oral administration, ubrogepant targets, binds to and blocks the activity of CGRP receptor. This prevents CGRP-mediated signaling. By blocking the CGRP-mediated pathways, ubrogepant is able to ease migraine symptoms, especially migraine headache pain. CGRP-mediated signaling plays a key role in migraine pathogenesis.
Also known as MK-1602, Ubrelvy, UBROGEPANT — per NCIT
Also identified as
- ATC N02CD04 per RXNORM
- NCIT NCIT:C152790 per NCIT
- SCTID 838467004 per RXNORM
- SCTID 838488008 per RXNORM
- UNII AD0O8X2QJR per RXNORM
Indications
| Disease | Relation | Source |
|---|---|---|
| Migraine | may treat | MEDRT · Public domain (U.S. Government work) |
| Migraine with aura | may treat | MEDRT · Public domain (U.S. Government work) |
| Migraine without aura | may treat | MEDRT · Public domain (U.S. Government work) |